HoldsUp

Mark Hyman, MD · 2025-07-23 · Mark Hyman (host), Eric Topol

Alzheimer's Starts 20 Years Before You Notice It — Here's What to Do Now

56 research-tied claims examined: 2 contradicted 9 overstated 3 context 36 supported 6 unverified

9

Overstated

0:00:06Eric Topoloverstatedmoderate

Plasma p-tau217 levels begin to rise 20 years before the onset of mild cognitive impairment.

"p-tau217 is the very first one that goes up and it starts 20 years before mild cognitive impairment. 20 years." (said at 0:00:06)

The speaker bundles two claims: that plasma p-tau217 is the 'very first' biomarker to change, and that it rises approximately 20 years before the onset of mild cognitive impairment (MCI). Longitudinal cohort data, such as a 25-year follow-up from the Women's Health Initiative Memory Study (PMID: 41805953), confirm that elevated baseline plasma p-tau217 levels are significantly associated with incident MCI and dementia up to 20 to 25 years before clinical manifestation. However, p-tau217 is not the 'very first' biomarker to become abnormal along the Alzheimer's disease continuum; trajectory modeling demonstrates that reductions in the plasma Aβ42/Aβ40 ratio precede increases in plasma phosphorylated tau species (PMID: 40539416).

0:22:45Eric Topoloverstatedmoderate

Blood-based p-tau217 testing performs as accurately as cerebrospinal fluid analysis and PET tau neuroimaging for Alzheimer's biomarker detection.

"because it's as good as a cerebrospinal fluid, it's as good as a PET tau scan, you know, which is a lot of radiation and hard to get" (said at 0:22:45)

While blood-based phosphorylated tau 217 (p-tau217) is an accurate biomarker for identifying Alzheimer's disease pathology (amyloid-beta positivity) and approaches the diagnostic accuracy of cerebrospinal fluid (CSF) testing in clinical screening, asserting that it is universally 'as good as a PET tau scan' is overstated. Cohort studies demonstrate that plasma p-tau217 assays primarily reflect early soluble tau phosphorylation in response to amyloid rather than the anatomical distribution or severity of insoluble neurofibrillary tangle pathology. For differentiating late-stage tau accumulation (A+T+ from A+T-), the accuracy of plasma p-tau217 assays decreases significantly (AUC 0.69–0.77), where tau-PET imaging remains the standard for staging.

0:27:10Eric Topoloverstatedhigh

In clinical trials, diabetic patients on GLP-1 drugs only lose 3 to 4 pounds on average, whereas non-diabetic individuals with obesity lose 40 to 80 pounds.

"And they kept saying to her, 'Well, Lotte, it's not going to work because the diabet- the diabetics only lose three or four pounds.' Well, now we see they we can get people to lose, you know, 40, 50, 60, 80 pounds. These drugs are so potent, and the reason we we it was blown was because the diabetics don't lose that weight" (said at 0:27:10)

While clinical trials consistently show that patients with type 2 diabetes experience somewhat less weight loss on GLP-1 receptor agonists than individuals without diabetes, the claimed disparity (3–4 pounds vs. 40–80 pounds) is a substantial exaggeration. In Phase 3 randomized trials of semaglutide 2.4 mg, adults with type 2 diabetes achieved an average weight loss of approximately 9.6% to 10% (around 20–22 pounds, as in the STEP 2 trial), far exceeding 3 to 4 pounds. Meanwhile, non-diabetic adults with overweight or obesity average approximately 15% to 17% weight loss (about 33–37 pounds across STEP 1, 3, and 5), rather than an average loss of 40 to 80 pounds.

0:18:59Mark Hyman (host)overstatedmoderate

On average, humans spend the last 20% of their lives in poor health or living with disease.

"we spend the last 20% of our lives in poor health that mean you do what you want and you're engaged and you feel good right and what's the point of living a long life if you feel like crap for the last 20% of your life" (said at 0:18:59)

The speaker overstates both the proportion of life spent in poor health and how that morbidity is distributed across a lifespan. Comprehensive data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD 2023) indicates that globally, individuals spend an average of 14.5% of their lives in poor health (a morbidity gap of approximately 10.7 years relative to total life expectancy), rather than 20%. In addition, demographic analyses demonstrate that health loss and disability accumulate across the adult life course rather than being strictly concentrated in the final years of life.

0:30:44Eric Topoloverstatedmoderate

The United States has the highest consumption of ultra-processed food in the world, with average consumption exceeding 70% of total diet and many individuals consuming 80% or more.

"and the US has the highest consumption in the world, 70% plus. And of course, a lot of people are 80% or more." (said at 0:30:44)

While systematic reviews confirm that the United States and the United Kingdom have the highest ultra-processed food (UPF) consumption rates internationally (generally exceeding 50% of total caloric intake), the speaker substantially overstates average US intake levels. Nationally representative data from NHANES show that the average contribution of UPFs to total energy intake is approximately 53% among adults and 62% among youth (overall average near 57–60%), well below the claimed average of '70% plus'.

0:53:25Eric Topoloverstatedmoderate

GLP-1 receptor agonists reduce cardiovascular inflammation prior to weight loss and prevent heart failure with preserved ejection fraction (HFpEF).

"We've already seen how GLP-1 drugs do that before any weight loss. So that should work well in people who aren't even obese, and we've seen how that can prevent heart—preserve ejection fraction heart failure, which is half of all heart failure, right? GLP-1s prevent that." (said at 0:53:25)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, demonstrate significant anti-inflammatory effects that occur partly independent of the magnitude of weight loss. In the STEP-HFpEF program (STEP-HFpEF and STEP-HFpEF DM randomized controlled trials), semaglutide significantly reduced C-reactive protein (CRP) levels, improved heart failure symptoms and physical limitations, and in pooled analyses reduced worsening heart failure events in patients with established heart failure with preserved ejection fraction (HFpEF). However, stating that GLP-1 drugs 'prevent HFpEF' and 'should work well in people who aren't even obese' overstates the evidence. The pivotal clinical trials specifically enrolled individuals with overweight or obesity (e.g., BMI ≥30 kg/m²), and evaluated the management of established obesity-related HFpEF and secondary worsening events rather than primary prevention in non-obese populations.

0:54:07Eric Topoloverstatedlow

AI analysis of retinal photographs can predict the onset of Alzheimer's disease 5 to 7 years in advance.

"So I have a picture of the retina and you do AI on it, and it tells you when you're going to have Alzheimer's, if you're going to have Alzheimer's 5 to 7 years in advance." (said at 0:54:07)

While research using deep learning on retinal imaging (such as fundus photography and optical coherence tomography) shows that retinal microvascular and structural features are associated with neurodegenerative risk factors and preclinical changes years before diagnosis, artificial intelligence cannot deterministically predict whether or precisely when an individual will develop Alzheimer's disease 5 to 7 years in advance. Existing deep learning models are investigational tools evaluated in large research cohorts (such as the UK Biobank) that demonstrate statistical risk associations and classification capabilities, but they are not validated clinical diagnostic tools that pinpoint future Alzheimer's onset.

1:00:15Eric Topoloverstatedmoderate

Failure to lower LDL cholesterol below 100 mg/dL or 70 mg/dL is associated with an increased risk of developing dementia.

"and Alzheimer's, as you know, accounts for 70% of dementia—that if you don't have the LDL lowered to, let's say, less than 100, less than 70, you're going to be at higher risk for dementia." (said at 1:00:15)

While observational studies and meta-analyses indicate that elevated midlife LDL cholesterol (e.g., >121 mg/dL) is associated with an increased risk of Alzheimer's disease, there is no evidence establishing that failing to achieve specific cardiovascular targets (<100 mg/dL or <70 mg/dL) increases dementia risk. Furthermore, an individual participant data meta-analysis of over 21,000 older adults found no significant association between LDL cholesterol levels and incident dementia or cognitive decline, and meta-analyses of randomized trials of intensive LDL-lowering therapies (such as PCSK9 inhibitors) have not shown a statistically significant reduction in the risk of dementia or Alzheimer's disease.

1:10:54Eric Topoloverstatedlow

Personalized neoantigen vaccines have achieved cures in patients with treatment-refractory pancreatic cancer and renal cell carcinoma.

"personalized neoantigen vaccines to cure pancreatic cancer, to cure renal cell carcinoma, intractable, that is people that failed everything else." (said at 1:10:54)

Personalized neoantigen vaccines have shown promising immunogenicity and improved recurrence-free survival in early phase I clinical trials, but they have not been shown to 'cure' pancreatic cancer or renal cell carcinoma (RCC), nor were the landmark trials conducted in patients with intractable disease who had failed all other therapies. In a phase I trial for pancreatic ductal adenocarcinoma (PDAC), an individualized mRNA neoantigen vaccine (autogene cevumeran) was administered as adjuvant therapy following complete surgical resection alongside chemotherapy and immunotherapy; 8 of 16 patients developed neoantigen-specific T-cell responses and experienced delayed disease recurrence, not confirmed cures. Similarly, a phase I trial of a neoantigen vaccine in RCC enrolled 9 patients with fully resected, high-risk disease in the adjuvant setting rather than treatment-refractory disease. These phase I trials demonstrate biological activity and preliminary feasibility in post-surgical settings, but neither establishes curative efficacy nor applies to intractable, end-stage disease.

  • partial: Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. (Nature 2023) · cited 1351x in the literature
    "Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA-lipoplex nanoparticles, we synthesized mRNA neoantigen vaccines in real time from surgically resected PDAC tumours. After surgery, we sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (a maximum of 20 neoantigens per patient) and a modified version of a four-drug chemotherapy regimen (mFOLFIRINOX)... At 18-month median follow-up, patients with vaccine-expanded T cells (responders) had a longer median recurrence-free survival (not reached) compared with patients without vaccine-expanded T cells (non-responders; 13.4 months, P = 0.003)." (abstract, results, passage verified)
    pubmedfull study (doi)
  • partial: A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. (Nature 2025) · cited 192x in the literature
    "Here we conducted a phase I trial (ClinicalTrials.gov identifier NCT02950766) to test a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage III or IV) with or without ipilimumab administered adjacent to the vaccine. At a median follow-up of 40.2 months after surgery, none of the 9 participants enrolled in the study had a recurrence of RCC." (abstract, results, passage verified)
    pubmedfull study (doi)

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.